Expanded Disability Status Scale (EDSS)
Quantifies neurological disability in MS patients on a 0-10 scale. Used to monitor disease progression and guide disease-modifying therapy decisions.
Score interpretation
EDSS 0–1.5: no disability; minimal signs at most.
→ Monitor for relapse; disease-modifying therapy as appropriate.
EDSS 2.0–3.5: fully ambulatory.
→ Review disease-modifying therapy; physiotherapy and occupational therapy as needed.
EDSS 4.0–5.5: ambulatory without aid, but walking distance restricted.
→ MS team review of disease-modifying therapy; multidisciplinary input; fatigue management.
EDSS 6.0–7.5: walking aid needed, or essentially restricted to a wheelchair.
→ Symptom management (spasticity, pain, bladder); mobility aids; specialist MS nursing.
EDSS 8.0–10: restricted to bed or chair, or helpless.
→ Supportive and palliative care focus; pressure area care; swallowing, bladder and bowel care.
Interpretation bands for the EDSS Score. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Cladribine · Multiple Sclerosis — Disease-Modifying Therapy
- Phenytoin / Fosphenytoin · Antiepileptic — Status Epilepticus (Second-Line)
- Levetiracetam (IV) · Antiepileptic — Status Epilepticus (Second-Line)
- Topiramate · Anticonvulsant (Multiple Mechanisms)
- Zonisamide · Antiepileptic — Multiple Mechanisms
- Levetiracetam IV (Status Epilepticus) · Antiepileptic — Second-Line Status Epilepticus
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.
